Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation
Growing evidence points to the potential of agonistic anti-CD40 mAb as adjuvants for vaccination against cancer. These appear to act by maturing DC and allowing them to prime CD8 cytotoxic T lymphocytes (CTL). While it is well established that optimal T-cell priming requires co-stimulation via B7:CD28, recent studies emphasize the contribution of TNF receptors to this process. To understand how anti-CD40 mAb triggers effective anti-tumor immunity we investigated the role of TNFR superfamily members CD27 and 4-1BB in the generation of this immunity and showed that, while partially dependent on 4-1BB:4-1BBL engagement, it is completely reliant on CD27:CD70 interactions. Importantly, blocking CD70, and to some extent 4-1BBL, during anti-CD40 treatment, prevented accumulation of tumor reactive T cells and subsequent tumor protection. However, it did not influence changes in DC number, phenotype, nor the activity of CTL once immunity was established. We conclude that CD27:CD70 and 4-1BB:4-1BBL interactions are needed for DC-driven accumulation of anti-tumor CTL following anti-CD40 mAb treatment. Finally, in support of the critical role for CD70:CD27, we show for the first time that agonistic anti-CD27 mAb given without a DC maturation signal completely protect tumor-bearing mice and provides a highly potent reagent for boosting anti-tumor T cell immunity.
4810-4815
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Taraban, Vadim Y.
d709dcbb-ff36-4514-85da-08ca68aafcd3
Crowther, Graham R.
0ef62e5c-2b5d-4c31-a3a5-8e74c23e024b
Rowley, Tania F.
3a29866f-3e2c-4ee8-8fe6-fd189ac1eb3d
Gray, Juliet C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Tutt, Alison L.
46ce577b-aea1-412d-84ea-fc4dab794469
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
2007
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Taraban, Vadim Y.
d709dcbb-ff36-4514-85da-08ca68aafcd3
Crowther, Graham R.
0ef62e5c-2b5d-4c31-a3a5-8e74c23e024b
Rowley, Tania F.
3a29866f-3e2c-4ee8-8fe6-fd189ac1eb3d
Gray, Juliet C.
12d5e17c-97bb-4d6d-8fc4-3914b730ed42
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Tutt, Alison L.
46ce577b-aea1-412d-84ea-fc4dab794469
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
French, Ruth R., Taraban, Vadim Y., Crowther, Graham R., Rowley, Tania F., Gray, Juliet C., Johnson, Peter W., Tutt, Alison L., Al-Shamkhani, Aymen and Glennie, Martin J.
(2007)
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.
Blood, 109 (11), .
(doi:10.1182/blood-2006-11-057216).
Abstract
Growing evidence points to the potential of agonistic anti-CD40 mAb as adjuvants for vaccination against cancer. These appear to act by maturing DC and allowing them to prime CD8 cytotoxic T lymphocytes (CTL). While it is well established that optimal T-cell priming requires co-stimulation via B7:CD28, recent studies emphasize the contribution of TNF receptors to this process. To understand how anti-CD40 mAb triggers effective anti-tumor immunity we investigated the role of TNFR superfamily members CD27 and 4-1BB in the generation of this immunity and showed that, while partially dependent on 4-1BB:4-1BBL engagement, it is completely reliant on CD27:CD70 interactions. Importantly, blocking CD70, and to some extent 4-1BBL, during anti-CD40 treatment, prevented accumulation of tumor reactive T cells and subsequent tumor protection. However, it did not influence changes in DC number, phenotype, nor the activity of CTL once immunity was established. We conclude that CD27:CD70 and 4-1BB:4-1BBL interactions are needed for DC-driven accumulation of anti-tumor CTL following anti-CD40 mAb treatment. Finally, in support of the critical role for CD70:CD27, we show for the first time that agonistic anti-CD27 mAb given without a DC maturation signal completely protect tumor-bearing mice and provides a highly potent reagent for boosting anti-tumor T cell immunity.
This record has no associated files available for download.
More information
Published date: 2007
Identifiers
Local EPrints ID: 44623
URI: http://eprints.soton.ac.uk/id/eprint/44623
ISSN: 0006-4971
PURE UUID: b6b75284-25d1-466f-8886-fb7a91a3e225
Catalogue record
Date deposited: 01 Mar 2007
Last modified: 16 Mar 2024 03:33
Export record
Altmetrics
Contributors
Author:
Ruth R. French
Author:
Vadim Y. Taraban
Author:
Graham R. Crowther
Author:
Tania F. Rowley
Author:
Alison L. Tutt
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics